Cancer Clinical Trials Information Platform in Hong Kong


  1. This serves merely as an information platform about cancer clinical trials operated by different institutions in Hong Kong. HKACS is not responsible for the contents, availability and operability of the trials listed.
  2. Respective institutions usually reserve all rights regarding the implementation and execution of their respective clinical trials.
  3. Patients usually need to satisfy a complex and stringent set of selection criteria before being selected/ included in certain clinical trials. Interested parties should contact respective institutions regarding further details of the trials


Cancer Site


*in alphabetical order (Last updated on 03/10/2024)


Stomach Cancer

Institution Study Title  
HKU (DS8201-A-U306/UW21-362) A Phase 3, multicenter, 2-arm randomized, open-label study of trastuzumab deruxtecan in subjects with HER2-positive metastatic and/or unresectable gastric or gastro-esophageal junction (GEJ) adenocarcinoma subjects who have progressed on or after a trastuzumab-containing regimen (DESTINY-Gastric04) Click for Details
CUHK (GAT013) A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with dvanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015) Click for Details
CUHK (GAT014)A Phase 3, multicenter, 2-arm randomized, open-label study of trastuzumab deruxtecan in subjects with HER2-positive metastatic and/or unresectable gastric or gastro-esophageal junction (GEJ) adenocarcinoma subjects who have progressed on or after a trastuzumab-containing regimen (DESTINY-Gastric04) Click for Details
CUHK (GAT015) A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102) Click for Details
CUHK (GAT017) A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician’s Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma) Click for Details


For Enquiry, please contact the respective institute, HKACS is not responsible for the outcomes of the clinical trials.